Maria Debiec-Rychter

Maria Debiec-Rychter

Auto-generated profile, based on publicly available information

Maria Debiec-Rychter

Department of Human Genetics University Hospitals Leuven Leuven Belgium

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
RSRaf Sciot
Raf Sciot
SJSandra Jacobs
Sandra Jacobs
FCFrank Van Calenbergh
Frank Van Calenbergh
PDPhilippe Demaerel
Philippe Demaerel
AWAgnieszka Wozniak
Agnieszka Wozniak
MDMaria Debiec‐Rychter
Maria Debiec‐Rychter

1 December 2020 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
IBIsabelle Vanden Bempt
Isabelle Vanden Bempt
SBSara Vander Borght
Sara Vander Borght
RSRaf Sciot
Raf Sciot
LSLien Spans
Lien Spans
SCSofie Claerhout
Sofie Claerhout
MDMaria Debiec‐Rychter
Maria Debiec‐Rychter

1 July 2017 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
BDBarbara Dewaele
Barbara Dewaele
LLLouis Libbrecht
Louis Libbrecht
GLGabriel Levy
Gabriel Levy
BBBenedicte Brichard
Benedicte Brichard
VVVanessa Vanspauwen
Vanessa Vanspauwen
MDMaria Debiec‐Rychter
Maria Debiec‐Rychter

1 January 2006 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
VWVéronique Winnepenninckx
Véronique Winnepenninckx
MDMaria Debiec-Rychter
Maria Debiec-Rychter
JBJeroen A M Beliën
Jeroen A M Beliën
PFPierre Fiten
Pierre Fiten
SMStefan Michiels
Stefan Michiels
JOJoost J van Den Oord
Joost J van Den Oord
Human pituitary tumour-transforming gene 1 or hPTTG1 is a proto-oncogene that codes for securin, a protein involved in sister chromatid separation. Based on previous microarray data, we studied the expression of hPTTG1/securin in melanocytic lesions. In contrast to nevi and radial growth phase melanomas, securin was expressed by scattered cells in the vertical growth phase, suggesting a role in tumour progression. In a series of 29 nodular and 29 superficial spreading melanomas, matched for all histological prognostic parameters, securin expression was significantly correlated with the nodular subtype (P=0.018) and not related to thickness. In other cancers, hPTTG1 is involved in various oncogenic pathways, including induction of neovascularisation and aneuploidy, and inhibition of p53 activity. We found coexpression of securin with wild-type p53 in the same neoplastic cells in a minority of melanomas. Expression of securin was significantly correlated with the extent of aneuploidy but not with basic fibroblast growth factor immunoreactivity or microvessel density. DNA cytometry revealed that nuclei-overexpressing securin frequently showed tetraploidy or aneuploidy. Our data show that hPTTG1 is frequently overexpressed in nodular melanoma, and suggest that hPTTG1 may act as an oncogene in the vertical growth phase, either by inhibiting anaphase, thereby causing aneuploidy and genomic instability, or by modulating the function of p53, thereby impairing apoptosis.

15 December 2021 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CLChe-Jui Lee
Che-Jui Lee
PSPatrick Schöffski
Patrick Schöffski
EMElodie Modave
Elodie Modave
TWTom Van Wezel
Tom Van Wezel
BBBram Boeckx
Bram Boeckx
AWAgnieszka Wozniak
Agnieszka Wozniak
Purpose: The European Organization for Research and Treatment of Cancer (EORTC) clinical phase II trial 90101 “CREATE” showed high antitumor activity of crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK)/ROS1, in patients with advanced inflammatory myofibroblastic tumor (IMFT). However, recent findings suggested that other molecular targets in addition to ALK/ROS1 might also contribute to the sensitivity of this kinase inhibitor. We therefore performed an in-depth molecular characterization of archival IMFT tissue, collected from patients enrolled in this trial, with the aim to identify other molecular alterations that could play a role in the response to crizotinib. Experimental Design: Twenty-four archival IMFT samples were used for histopathological assessment and DNA/RNA evaluation to identify gene fusions, copy-number alterations (CNA), and mutations in the tumor tissue. Results were correlated with clinical parameters to assess a potential association between molecular findings and clinical outcomes. Results: We found 12 ALK fusions with 11 different partners in ALK-positive IMFT cases by Archer analysis whereas we did not identify any ROS1-rearranged tumor. One ALK-negative patient responding to crizotinib was found to have an ETV6–NTRK fusion in the tumor specimen. The CNA profile and mutational landscape of IMFT revealed extensive molecular heterogeneity. Loss of chromosome 19 (25% of cases) and PIK3CA mutations (9% of cases) were associated with shorter progression-free survival in patients receiving crizotinib. Conclusions: We identified multiple genetic alterations in archival IMFT material and provide further insight into the molecular profile of this ultra-rare, heterogeneous malignancy, which may potentially translate into novel treatment approaches for this orphan disease.

22 February 2024 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
JBJef Baelen
Jef Baelen
BDBarbara Dewaele
Barbara Dewaele
MDMaria Debiec-Rychter
Maria Debiec-Rychter
RSRaphael Sciot
Raphael Sciot
PSPatrick Schöffski
Patrick Schöffski
IBIsabelle Vanden Bempt
Isabelle Vanden Bempt
Soft-tissue and bone tumors represent a heterogeneous group of tumors encompassing more than 100 histologic subtypes today. Identifying genetic aberrations increasingly is important in these tumors for accurate diagnosis. Although gene mutations typically are detected by second-generation sequencing, the identification of structural variants (SVs) and copy number alterations (CNAs) remains challenging and requires various cytogenetic techniques including karyotyping, fluorescence in situ hybridization, and arrays, each with important limitations. Optical Genome Mapping (OGM), a non-sequencing-based technique for high-resolution detection of SVs and CNAs, was applied in a retrospective series of diagnostic soft-tissue and bone tumor samples. Sample preparation was successful in 38 of 53 cases, with the highest success rate in nonadipocytic soft-tissue tumors (24 of 27 cases; 89%). In 32 of 35 cases carrying a diagnostic SV or CNA, OGM identified the aberration (91%), including a POU2AF3::EWSR1 fusion in a round cell sarcoma and a translocation t(1;5)(p22;p15) in a myxoinflammatory fibroblastic sarcoma. Interestingly, OGM shed light on the genomic complexity underlying the various aberrations. In five samples, OGM showed that chains of rearrangements generated the diagnostic fusion, three of which involved chromoplexy. In addition, in nine samples, chromothripsis was causal to the formation of giant marker/ring/double-minute chromosomes. Finally, compared with standard-of-care cytogenetics, OGM revealed additional aberrations, requiring further investigation of their potential clinical relevance.